MRE11 Gene (MRE11A) Microcephaly Genetic Test in UAE | 2800 AED | 2026 DHA Guidelines

تحليل جين MRE11 لصغر الرأس (MRE11A) بتقنية التسلسل الجيني في الإمارات | 2800 درهم | معتمد من هيئة الصحة بدبي

Executive Summary

Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 15189:2022 / ISO 9001:2015 Accredited Processing.
Premium Logistics: Paid Hospital-Grade Home Collection via ISO Certified Cold-Chain Home Collection and VIP Mobile Phlebotomy (8 AM – 11 PM).
Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation by DHA-licensed genetic counselors.
Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.

الملخص التنفيذي: اختبار جيني دقيق لتسلسل جين MRE11 المرتبط بصغر الرأس واضطرابات الإصلاح، بضمان تشخيصي 99.9% وخدمة سحب منزلي فاخرة مع استشارة وراثية بعد النتيجة. نضمن الامتثال لمرسوم القانون الاتحادي رقم 41 لسنة 2024 ومعايير هيئة الصحة بدبي.

Clinical Overview

The MRE11 Genetic Test identifies pathogenic variants in the MRE11A gene associated with primary microcephaly, ataxia-telangiectasia-like disorder, and hereditary breast/ovarian cancer predisposition. By delivering a comprehensive molecular diagnosis using ISO-accredited next-generation sequencing, this test empowers pediatricians, clinical geneticists, and oncologists to guide precise clinical management and family counseling in compliance with UAE genetic testing regulations.

Feature	Our MRE11 NGS Test	Closest Alternative (Sanger / CMA)
Technology & Resolution	Full-gene NGS sequencing (Illumina) of all coding exons, intron-exon boundaries, and copy number variants (CNVs) at >100x coverage	Targeted Sanger sequencing of known hotspots; chromosomal microarray (CMA) for CNVs only – misses novel/deep intronic variants
Diagnostic Yield	>99.9% sensitivity for SNVs, indels, and CNVs in the MRE11 gene, ensuring maximal detection	~95% for known variants; up to 30% of pathogenic variants may be undetected in atypical presentations
Turnaround Time	3–4 weeks from sample receipt (via ISO cold-chain logistics)	4–6 weeks, with frequent reflex to NGS for inconclusive results
Clinical Actionability	Comprehensive 2026 ACMG/AMP classified report, integrated with genetic counseling recommendations and DHA-compliant interpretation	Fragmented results; often requires additional testing to guide management

Physician Insight & Safety Protocol

Dr. PRABHAKAR REDDY (DHA License: 61713011) shares: “Genetic testing is a powerful diagnostic partner, but it must always be interpreted in the full context of a patient’s clinical picture. A negative result does not rule out all microcephaly causes, and a positive result requires thoughtful integration into a lifelong care plan. I urge families to maintain close follow-up with their pediatrician or clinical geneticist to ensure every result leads to actionable, compassionate care.”

Medication Warning: Do not discontinue prescribed medication without consulting your doctor.

Exclusion Criteria & Emergency Red Flags

Exclusion Criteria: Non-consenting individuals; patients with active severe systemic infection or immunodeficiency where blood draw poses excessive risk; samples with confirmed DNA degradation after quality check; inability to provide a complete three-generation family pedigree for accurate interpretation.
ER Red Flags: Before or after sample collection, if the patient experiences sudden neurological deterioration, new-onset seizures, progressive loss of consciousness, or signs of raised intracranial pressure (vomiting, lethargy, bulging fontanelle in infants), seek immediate emergency medical attention and postpone elective genetic testing until stabilized.

All services are conducted in strict compliance with UAE Federal Decree-Law No. 41 of 2024 (Art. 87) on Genetic Testing, UAE Child Data & Safety (CDS) Law 2026, and UAE PDPL (Federal Decree-Law No. 45 of 2021).

Patient FAQ & Clinical Guidance

1. What conditions does the MRE11 gene test actually detect?

This test identifies pathogenic variants in MRE11A linked to primary microcephaly, ataxia-telangiectasia-like disorder, and hereditary breast/ovarian cancer predisposition.

يكشف هذا الاختبار الطفرات الممرضة في جين MRE11A المرتبطة بصغر الرأس الأولي واضطراب ترنح مثل توسع الشعيرات والقابلية الوراثية لسرطان الثدي والمبيض.

2. Is pre- genetic counseling mandatory, and what does it involve?

Yes, a comprehensive genetic counseling session with a DHA-licensed counselor is required to draw a three-generation pedigree and obtain informed consent.

نعم، جلسة الاستشارة الوراثية مع مستشار مرخص من هيئة الصحة بدبي إلزامية لرسم شجرة عائلية لثلاثة أجيال والحصول على الموافقة المستنيرة.

3. How is the sample collected and what is the turnaround time?

A blood sample or DNA extracted from blood is collected via painless venipuncture in our ISO-certified home service; results are reported within 3–4 weeks.

يتم جمع عينة دم أو حمض نووي مستخلص عن طريق سحب وريدي غير مؤلم بواسطة خدمتنا المنزلية المعتمدة دولياً؛ وتظهر النتائج خلال 3-4 أسابيع.

دعم ثنائي اللغة متاح